| Name | Retatrutide sodium salt |
| Description | Retatrutide sodium salt is a potent triple agonist peptide for glucagon receptor (GCGR), glucose-dependent proinsulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R) Retatrutide sodium salt is used in the study of type 2 diabetes and obesity. |
| In vitro | Retatrutide sodium salt exhibits activity against human GCGR, GIPR, and GLP-1R, with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively[1].
In mouse models, Retatrutide sodium salt demonstrates activity against GCGR, GIPR, and GLP-1R, with EC50 values of 2.32, 0.191, and 0.794 nM, respectively[1].
The binding affinities of Retatrutide sodium salt for human GCGR, GIPR, and GLP-1R are characterized by Ki values of 5.6, 0.057, and 7.2 nM, respectively[1].
For mouse GCGR, GIPR, and GLP-1R, Retatrutide sodium salt exhibits binding affinities with Ki values of 73, 2.8, and 1.3 nM, respectively[1]. |
| In vivo | Retatrutide sodium salt, administered via subcutaneous injection at a single dose of 0.47 mg/kg, engages with the glucagon receptor (GCGR) in vivo and improves glucose tolerance in an intraperitoneal glucose tolerance test (ipGTT) through activation of GIP or GLP-1 receptors[1].
With subcutaneous injections at a dose of 10 mL/kg every 3 days for a cycle of 21 days, Retatrutide sodium salt induces significant weight loss and increased energy expenditure through activation of the glucagon-like peptide-1 (GLP-1) receptor[1].
Retatrutide sodium salt demonstrates safety and tolerability in these studies[1]. |
| Storage | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | GlucagonReceptor | Glucagon Receptor | GLP-1 | GCGR | Flagelin22sodiumsalt(304642919freebase) |
| Inhibitors Related | Exendin-4 | Exendin-4 acetate | Semaglutide | (S, R)-LSN 3318839 | NNC 92-1687 | Liraglutide | Semaglutide Acetate | 6α-Methylprednisolone 21-hemisuccinate sodium salt | MK-0626 | Orforglipron | Tirzepatide Acetate(2023788-19-2 free base) | LSN3318839 |
| Related Compound Libraries | Peptide Compound Library |
United States
